RecruitingRecruiting
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
NCT05265429 · Dana-Farber Cancer Institute
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to:
* Better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease
* Better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger
* Examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients
* Improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger
Study procedures will include:
* Collecting information from participants' medical record and two (2) short questionnaires
* Collecting blood and/or saliva samples
* Collecting tumor tissue samples (optional)
It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.
Eligibility criteria
Inclusion Criteria:
* Age 45 and under at lung cancer diagnosis
* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
* Provision of written informed consent
* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent
Exclusion Criteria:
* Individuals who decline to sign consent
* Individuals who are unable to give consent or assent and are without a designated healthcare proxy
* Compromise of patient diagnosis or staging if tissue is used for research
Study design
Enrollment target: 500 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2023-01-01
Estimated completion: 2027-08-01
Last updated: 2025-10-29
Interventions
Genetic: Data and Specimen Collection
Primary outcomes
- • Repository of specimens and data (5 years or study closure)
Sponsor
Dana-Farber Cancer Institute · other
Contacts & investigators
ContactPasi A Janne, MD, PhD · contact · Pasi_Janne@dfci.harvard.edu · 617-632-6036
InvestigatorPasi A Janne, MD, PhD · principal_investigator, Dana-Farber Cancer Institute
All locations (4)
Massachusetts General HospitalRecruiting
Boston, Massachusetts, United States
Beth Israel Deaconess Medical CenterNot Yet Recruiting
Boston, Massachusetts, United States
Brigham and Women's HospitalNot Yet Recruiting
Boston, Massachusetts, United States
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States